Last updated on January 2016

Clinical Efficacy and Safety of a Subcutaneous Immunotherapy With gpASIT+ in Patients With Grass Pollen-induced Allergic Rhinoconjunctivitis


Brief description of study

gpASIT+TM product is based on highly purified allergen fragments obtained from grass pollen. The purpose of this study is to demonstrate the clinical efficacy and safety of a subcutaneous immunotherapy with gpASIT+™ in patients with grass pollen-induced allergic rhinoconjunctivitis compared to placebo.

Clinical Study Identifier: NCT02560948

.

Contact Investigators or Research Sites near you

Start Over

Please choose location

View all locations

Claus Bachert, Prof Dr

University Hospital Ghent
Ghent, Belgium
  Connect »

Enrico Iemoli, MD

Clinica dell'Azienda Opsedaliera Luigi Sacco
Milano, Italy
  Connect »

Joachin Sastre, Prof, Dr

Fundacion Jim nez Diaz
Madrid, Spain
  Connect »